

## Proteogenomic analyses identify coagulation factor XI as a thromboinflammatory mediator of long COVID

Art Schuermans<sup>1,2,3,\*</sup>, Andreas Verstraete<sup>1,4</sup>, Vilma Lammi<sup>5</sup>, Tomoko Nakanishi<sup>6-10</sup>, Maddalena Ardissino<sup>11,12</sup>, Jef Van den Eynde<sup>1</sup>, Benjamin B. Sun<sup>13</sup>, Marios K. Georgakis<sup>2,14,15</sup>, Johan Van Weyenbergh<sup>16</sup>, Adam J. Lewandowski<sup>17</sup>, Betty Raman<sup>18</sup>, Hanna M. Ollila<sup>2,3,5,19</sup>, Stephen Burgess<sup>20</sup>, Pradeep Natarajan<sup>2,3,21</sup>, Michael C. Honigberg<sup>2,3,21</sup>, Kathleen Freson<sup>1</sup>, Thomas Vanassche<sup>1,4</sup>, Peter Verhamme<sup>1,4</sup>.

<sup>1</sup> KU Leuven Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Leuven, Belgium

<sup>2</sup> Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA

<sup>3</sup> Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA

<sup>4</sup> UZ Leuven Department of Cardiovascular Diseases, Leuven, Belgium

<sup>5</sup> Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland

<sup>6</sup> Department of Human Genetics, McGill University, Montréal, QC, Canada

<sup>7</sup> Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, QC, Canada

<sup>8</sup> Kyoto-McGill International Collaborative Program in Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

<sup>9</sup> Department of Genome Informatics, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan

<sup>10</sup> Japan Society for the Promotion of Science, Tokyo, Japan

<sup>11</sup> BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

<sup>12</sup> National Heart and Lung Institute, Imperial College London, London, UK

<sup>13</sup> Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

<sup>14</sup> Institute for Stroke and Dementia Research, Ludwig Maximilian University of Munich, Munich, Germany

<sup>15</sup> Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

<sup>16</sup> Laboratory of Clinical and Epidemiological Virology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium

<sup>17</sup> Nuffield Department of Population Health, University of Oxford, Oxford, UK

<sup>18</sup> Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

<sup>19</sup> Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA

<sup>20</sup> MRC Biostatistics Unit, University of Cambridge, Cambridge, UK

<sup>21</sup> Department of Medicine, Harvard Medical School, Boston, MA, USA

**\*Correspondence to:**

Art Schuermans

KU Leuven Department of Cardiovascular Sciences

Center of Molecular and Vascular Biology

Herestraat 49 (box 911)

3000 Leuven, Belgium

Tel: +32 16 343491

Fax: +32 16 343493

Email: [aschuerm@broadinstitute.org](mailto:aschuerm@broadinstitute.org)

**Manuscript word count (excluding methods): 3,126**

**Abstract word count: 148**

**Figure/table count: 4**

**Reference count: 54**

1 **Abstract**

2 SARS-CoV-2 infection can result in long COVID, characterized by post-acute  
3 symptoms from multiple organ systems. Current hypotheses on mechanisms underlying long  
4 COVID include persistent inflammation and dysregulated coagulation; however, precise  
5 mechanisms and causal mediators remain unclear. Here, we tested the associations of  
6 genetic instruments for 49 complement and coagulation factors from the *UK Biobank*  
7 ( $N=34,557$ ) with long COVID in the *Long COVID Host Genetics Initiative* ( $N=997,600$ ).  
8 Primary analyses revealed that genetically predicted higher factor XI increased long COVID  
9 risk (odds ratio, 1.17 [95% confidence interval, 1.08-1.27] per standard deviation;  $P=1.7\times 10^{-4}$ ).  
10 This association was robust to sensitivity analyses using pleiotropy-robust methods and  
11 different genetic instruments and was replicated using proteogenomic data from an Icelandic  
12 cohort. Genetically predicted factor XI was also associated with venous thromboembolism,  
13 but not with acute COVID-19 or long COVID-resembling conditions. Collectively, these  
14 findings provide genetic evidence implicating factor XI in the biology of long COVID.

15 **Main**

16 Infection with SARS-CoV-2 leads to different acute clinical manifestations, ranging  
17 from mild respiratory disease to multi-organ dysfunction. It is becoming increasingly clear  
18 that infection with SARS-CoV-2 also has chronic effects, with epidemiological data  
19 suggesting that 5-10% of acutely infected individuals experience persistent complaints three  
20 months after infection<sup>1</sup>. These post-acute symptoms, also referred to as “long COVID”, are  
21 not limited to the respiratory tract but involve various organ systems<sup>2</sup>. Common  
22 manifestations include physical (e.g., fatigue, post-exertional malaise, and shortness of  
23 breath), cognitive (e.g., memory loss and cognitive impairment), and psychological (e.g.,  
24 anxiety and depression) symptoms<sup>3</sup>. Up to 85% of long COVID patients report ongoing  
25 complaints even after one year<sup>4,5</sup>. Despite its high prevalence and impact on quality of life,  
26 clinical strategies for the prevention and treatment of long COVID remain limited.

27 The lack of disease-specific therapies for long COVID can be partially ascribed to an  
28 incomplete understanding of its molecular drivers. Currently hypothesized mechanisms  
29 underlying long COVID include immune dysregulation, virus-induced inflammation, and  
30 endothelial dysfunction<sup>3</sup>. For instance, in a prospective cohort study of 1,837 adults  
31 hospitalized with COVID-19, selected blood markers of coagulation (i.e., fibrinogen and D-  
32 dimer relative to C-reactive protein) predicted cognitive defects at 6-12 months after  
33 infection<sup>6</sup>. Similarly, a recent proteomic study of 113 individuals infected with SARS-CoV-2  
34 revealed that the development of long COVID was associated with changes to blood proteins  
35 indicative of persistent complement activation and altered coagulation<sup>7</sup>. In the same study,  
36 circulating levels of factor XI (FXI) were elevated in those with compared to those without  
37 long COVID, pointing towards thromboinflammation as a possible mechanism contributing to  
38 long COVID development<sup>7,8</sup>. Despite these findings, it remains unclear whether the  
39 complement and coagulation pathways are causally involved in long COVID.

40 Recent work has identified genetic variants associated with plasma protein levels<sup>9,10</sup>,  
41 facilitating the identification of causal mechanisms for human diseases using Mendelian  
42 randomization (MR)<sup>11,12</sup>. MR is an epidemiological method that uses the random assortment  
43 of alleles at conception, which leads to an effective randomization of individuals to higher or  
44 lower genetically predicted values for phenotypes such as changes in plasma protein levels,  
45 enabling causal inference<sup>13,14</sup>. This effective randomization limits the risk of bias due to  
46 confounding and reverse causation and can therefore provide support for a causal  
47 relationship between an exposure and outcome of interest<sup>15,16</sup>. Previous MR analyses have  
48 identified causal mediators of acute COVID-19<sup>17,18</sup>, with clinical trial data confirming some of  
49 these (e.g., the interleukin-6 receptor) as effective drug targets in human patients<sup>19,20</sup>. Given  
50 the limitations and high costs associated with traditional methods for identifying drug targets,

51 genetic approaches such as MR may also help prioritize new causal biomarkers and  
52 therapeutic targets for long COVID<sup>21</sup>.

53 Here, we used MR to test the hypothesis that the complement and coagulation  
54 systems contribute causally to long COVID. We constructed genetic instruments for plasma  
55 proteins involved in the complement and/or coagulation pathways and estimated their causal  
56 effects on the development of long COVID. Sensitivity analyses probed the robustness of the  
57 observed associations and replication analyses evaluated whether these associations  
58 persisted using separate datasets. Finally, we evaluated the effects of the identified proteins  
59 on different conditions to gain insights into the biological mechanisms behind the observed  
60 associations.

61

## 62 **Results**

### 63 *Overall analysis approach*

64 The study design is shown in **Fig. 1**. First, we identified all complement- and  
65 coagulation-related proteins using the Kyoto Encyclopedia of Genes and Genomes (KEGG)  
66 database<sup>22</sup>. For each protein, we selected near-uncorrelated genetic variants (linkage  
67 disequilibrium  $R^2 < 0.1$ ) associated with circulating levels of that protein ( $P < 1 \times 10^{-6}$ ) near the  
68 corresponding protein-encoding gene (within 200 kilobases). These genetic variants are also  
69 referred to as *cis*-protein quantitative trait loci (*cis*-pQTLs) and facilitate adherence to the  
70 core assumptions of MR<sup>12,23,24</sup> (**Fig. 1; Supplemental Methods**). For each protein, all *cis*-  
71 pQTLs were combined into one statistical entity, i.e., a genetic instrument (**Supplemental**  
72 **Methods**).

73 Once all genetic instruments were constructed, we tested the association of each  
74 protein's genetic instrument with long COVID. The present study used a two-sample MR  
75 approach, which uses genetic data from one genome-wide association study (GWAS) to  
76 construct a genetic instrument for the exposure of interest (e.g., the UK Biobank) and genetic  
77 data from a second, separate GWAS to test the association of this genetic instrument with  
78 the outcome of interest (e.g., the Long COVID Host Genetics Initiative)<sup>15,25</sup>.

79

### 80 *Characteristics of the included cohorts*

81 Genetic instruments for circulating complement and coagulation factors were  
82 constructed in the UK Biobank. The characteristics of this cohort and its participants have  
83 been described previously<sup>9</sup>. In brief, genetic instruments were built using proteogenomic data  
84 from 34,557 participants with European ancestry of the 46,595 participants in total that were  
85 randomly selected for proteomic measurements. Of those, approximately 48.8% were male  
86 and the mean age was 56.7 years<sup>9</sup>.

87 The associations of each protein's genetic instruments with long COVID was tested in  
88 the Long COVID Host Genetics Initiative, characteristics of which are provided in  
89 **Supplementary Table 1** and have been described previously<sup>26</sup>. While the Long COVID Host  
90 Genetics Initiative included 25 cohorts (cases:  $n=6,450$ ; controls:  $n=1,093,995$ ), primary  
91 analyses excluded participants who met the criteria for long COVID but did not have a prior  
92 test-verified SARS-CoV-2 infection and therefore only used data from 12 cohorts (cases:  
93  $n=3,018$ ; controls:  $n=994,582$ ). Of the 12 included cohorts, the majority (83.3%) used  
94 questionnaires rather than electronic health data to ascertain long COVID (**Supplementary**  
95 **Table 1**). Approximately 99.1% of participants included in these cohorts had European  
96 ancestry, 48.0% were male, and the weighted mean age across cohorts was 62.3 years<sup>26</sup>.  
97 Around 30.5% of long COVID cases had a history of hospitalization due to COVID-19.

98

#### 99 *Construction of genetic instruments for complement- and coagulation-related proteins*

100 A total of 69 candidate complement- and coagulation-related proteins were identified  
101 using the KEGG pathway database<sup>22</sup> (**Supplementary Table 2**). Of those, 49 (71.0%) were  
102 available and had at least one valid *cis*-pQTL (i.e., a genetic variant within 200 kilobases of  
103 the protein-encoding gene with  $P < 1 \times 10^{-6}$  and linkage disequilibrium  $R^2 < 0.1$ ) based on  
104 proteogenomic data from up to 34,557 UK Biobank participants (**Supplementary Tables 2-**  
105 **3**). Variants used for each protein-specific genetic instrument are listed in **Supplementary**  
106 **Table 4**. All estimated  $F$ -statistics were  $> 20$ , indicating low risk of weak instrument bias.

107

#### 108 *Genetic associations of complement- and coagulation-related proteins with long COVID*

109 Primary analyses identified one protein that was genetically associated with long  
110 COVID at Bonferroni-adjusted  $P < 1.0 \times 10^{-3}$  considering 49 tested proteins (**Fig. 2**;  
111 **Supplementary Table 5**). Higher genetically predicted levels of plasma FXI were associated  
112 with higher odds of having long COVID (OR, 1.17 [95% CI, 1.08-1.27] per SD;  $P = 1.7 \times 10^{-4}$ ).

113 Although not reaching Bonferroni significance, another 14 proteins had nominally  
114 significant associations with long COVID. Higher genetically predicted levels of the factor II  
115 receptor (F2R, also known as PAR1), complement C1s subcomponent (C1S) and C1q  
116 subcomponent subunit A (C1QA),  $\alpha$ -2-antiplasmin (SERPINF2), C4b-binding protein ( $\beta$ -  
117 chain; C4BPB), carboxypeptidase 2 (CPB2), and the urokinase plasminogen activator  
118 surface receptor (PLAUR) were nominally associated with higher odds of having long  
119 COVID. In contrast, higher genetically predicted levels of factor XII (F12), thrombomodulin  
120 (THBD), heparin cofactor 2 (SERPIND1), tissue factor pathway inhibitor (TFPI), complement  
121 factor I (CFI), complement factor C7 (C7), and C1 inhibitor (SERPING1) were nominally  
122 associated with lower odds of having long COVID.

123

124 *Genetic associations of FXI with long COVID in sensitivity and replication analyses*

125 To evaluate the role of horizontal pleiotropy (i.e., effects of a genetic instrument on  
126 the outcome outside of its effects on the exposure) in the genetic association of circulating  
127 FXI with long COVID, we tested the association of genetically predicted plasma FXI with long  
128 COVID using MR-Egger (**Supplemental Fig. 1**). Analysis using MR-Egger suggested a  
129 pleiotropy-robust association of genetically predicted plasma FXI with long COVID (OR, 1.18  
130 [95% CI, 1.04-1.34] per SD;  $P=8.1\times 10^{-3}$ ), with a nonsignificant MR-Egger intercept term  
131 ( $P_{\text{intercept}}=0.84$ ), suggesting that *cis*-pQTLs associated with FXI affect long COVID risk  
132 through plasma levels of FXI rather than through other mediators. We also performed  
133 sensitivity analyses using different linkage disequilibrium  $R^2$   
134 ( $R^2<0.001/R^2<0.01/R^2<0.1/R^2<0.2$ ) and  $P$ -value ( $P<1\times 10^{-4}/P<1\times 10^{-6}/P<1\times 10^{-8}$ ) thresholds to  
135 construct genetic instruments. The association of genetically predicted FXI with long COVID  
136 was directionally consistent across all tested instrument construction parameters (**Fig. 3**;  
137 **Supplementary Table 6**) and persisted when removing a single potentially reverse causal  
138 genetic variant using Steiger filtering (OR, 1.15 [95% CI, 1.07-1.24] per SD;  $P=2.5\times 10^{-4}$ ).

139 Replication analyses tested whether the observed associations persisted against  
140 stricter criteria to define long COVID controls (restricting to proven controls; i.e., all  
141 participants with proven SARS-CoV-2 infection who did not meet long COVID criteria<sup>26</sup>) as  
142 well as a different proteomic profiling method (the aptamer-based SomaScan platform  
143 instead of Olink) in an external cohort including 35,559 Icelanders genotyped by deCODE<sup>10</sup>.  
144 Using stricter long COVID control criteria, FXI was associated with 1.15-fold odds of having  
145 long COVID (95% CI, 1.05-1.26;  $P=1.9\times 10^{-3}$ ) per SD increase in genetically predicted levels.  
146 Using proteogenomic data from deCODE, genetically predicted FXI was associated with  
147 1.17-fold odds of having long COVID (95% CI, 1.08-1.27;  $P=1.5\times 10^{-4}$ ) per SD. Additional  
148 models using these replication datasets, as well as the aforementioned set of  $R^2$  and  $P$ -value  
149 thresholds to construct genetic instruments, also yielded directionally consistent results (**Fig.**  
150 **3; Supplementary Tables 7-8**).

151 We also performed colocalization analyses to test for distinct or shared causal genetic  
152 variants between plasma FXI and long COVID (see also **Supplementary Methods**).  
153 Considering the fact that colocalization methods are developed in the context of GWASs  
154 rather than *cis*-MR studies<sup>27</sup>, and given previous analyses providing inconclusive  
155 colocalization evidence for the majority of strong and robust *cis*-MR associations<sup>12</sup>, the main  
156 purpose of these analyses was to exclude the possibility that there were distinct causal  
157 variants. Reassuringly, there was no evidence for distinct causal variants between FXI and  
158 long COVID (posterior probability for distinct causal variants [ $H_3$ ]: 7.5%; posterior probability  
159 for shared causal variants [ $H_4$ ]: 1.7%).

160

161 *Association of predicted FXI levels with venous thromboembolism, bleeding, and long*  
162 *COVID-resembling phenotypes*

163         Next, we tested the associations of genetically predicted FXI levels with bleeding and  
164 venous thromboembolism. In line with clinical evidence showing that FXI levels are  
165 associated with venous thromboembolism<sup>28,29</sup>, higher genetically predicted FXI levels were  
166 associated with a higher risk of venous thromboembolism (OR, 1.71 [95% CI, 1.62-1.80] per  
167 SD;  $P=5.6\times 10^{-91}$ ), further supporting the use of *cis*-MR to identify causal associations of  
168 circulating FXI with clinical conditions. There was no genetic association of plasma FXI levels  
169 with risk of bleeding (OR, 0.99 [95% CI, 0.97-1.01] per SD;  $P=0.42$ ).

170         In addition, to gain insights into the mechanisms driving the association of FXI with  
171 long COVID, we tested the associations of genetically predicted FXI levels with long COVID-  
172 resembling phenotypes. Genetically predicted levels of circulating FXI showed no association  
173 with acute COVID-19 (OR, 0.96 [95% CI, 0.90-1.03] per SD;  $P=0.25$ ). This indicates that the  
174 genetic association between FXI levels and long COVID is not driven by an increased  
175 susceptibility to acute symptoms resulting from SARS-CoV-2 infection. Additionally,  
176 genetically predicted levels of FXI were not associated with a higher risk of long COVID-  
177 resembling conditions or symptoms such as memory loss or mood disorders (**Fig. 4;**  
178 **Supplementary Table 9**). Postviral fatigue was the only condition with an effect estimate  
179 within the 95% CI of long COVID (OR, 1.13 [95% CI, 0.88-1.44] per SD;  $P=0.35$ ), although  
180 this association was likely underpowered due to a small number of cases in FinnGen's  
181 GWAS of postviral fatigue (cases:  $n=195$ ; controls:  $n=382,198$ ). These findings support the  
182 notion that the genetic association of plasma FXI with long COVID represents a specific  
183 association, wherein FXI plays a role in the pathophysiology of long COVID (and potentially  
184 other postviral conditions) rather than the occurrence of its individual, non-specific clinical  
185 symptoms.

186

187 **Discussion**

188         Using genetic data from multiple cohorts, we tested the associations of genetically  
189 predicted levels of different complement- and coagulation-related proteins with long COVID.  
190 Primary analyses identified an association of higher genetically predicted plasma levels of  
191 FXI with long COVID. The genetic association of FXI with long COVID was robust to multiple  
192 sensitivity analyses using pleiotropy-robust methods and different genetic instruments, and  
193 was replicated using data from an external Icelandic cohort. Additional analyses testing the  
194 genetic associations of plasma FXI with a range of different phenotypes did not reveal any  
195 associations with long COVID-resembling conditions (e.g., memory loss or mood disorders),  
196 suggesting a specific role for FXI in the pathophysiology of long COVID. Collectively, these



197 findings provide new mechanistic insights and identify a potential therapeutic target for long  
198 COVID.

199 Our findings suggest FXI is involved in the development of long COVID. FXI is a  
200 coagulation factor encoded by the *F11* gene that circulates as an inactive zymogen in the  
201 bloodstream until it is cleaved by the activated form of factor XII or thrombin<sup>30</sup>. The cleaved  
202 form of FXI activates factor IX, thereby propagating the intrinsic coagulation pathway, also  
203 known as the contact activation pathway, and amplifying the coagulation cascade.  
204 Epidemiological, preclinical, and clinical studies have established that higher FXI levels  
205 increase the risk of thrombosis, prompting the clinical evaluation of FXI inhibitors in phase 3  
206 trials for the prevention of thromboembolic events in various clinical contexts<sup>31,32</sup>. In addition  
207 to its established role in promoting thrombosis, FXI has also been implicated in inflammatory  
208 and immune-related processes<sup>30,33</sup>. Recent evidence indicates that FXI can induce vascular  
209 inflammation without causing overt thrombosis<sup>34</sup>. Experimental data also suggest that  
210 pharmacological inhibition of FXI can mitigate inflammation and attenuate coagulopathy in  
211 mice with polymicrobial sepsis<sup>35</sup>. Similarly, inhibition of FXI in mice with experimental  
212 autoimmune encephalomyelitis leads to improved disease severity as well as reduced  
213 vascular disruption and immune cell migration<sup>36</sup>. These findings collectively suggest that FXI  
214 is an important thromboinflammatory mediator with effects that extend beyond coagulation,  
215 including vascular dysfunction and neuroinflammation.

216 Furthermore, consistent with the notion that thromboinflammation may contribute to  
217 long COVID, prior studies have suggested involvement of thrombosis-related pathways in the  
218 pathophysiology of acute COVID-19<sup>37,38</sup>. During the early stages of the pandemic, one in four  
219 COVID-19 patients admitted to the intensive care unit experienced venous thromboembolism  
220 despite standard dose thromboprophylaxis<sup>39</sup>. Mechanistic research suggests that this  
221 heightened risk of venous thromboembolism partially reflects a systemic COVID-19-  
222 associated coagulopathy involving immune response dysregulation, endothelial cell  
223 dysfunction, and hypercoagulability<sup>38</sup>. For instance, transcriptomic profiling of  
224 bronchoalveolar lavage fluid from patients with vs. without acute COVID-19 demonstrated  
225 differential regulation of genes encoding coagulation-related proteins (e.g., FXI)<sup>40-42</sup>,  
226 suggesting involvement of these proteins in COVID-19-associated coagulopathy. In addition,  
227 selected blood markers of coagulation and inflammation (i.e., fibrinogen and D-dimer relative  
228 to C-reactive protein) have been shown to predict cognitive defects in patients hospitalized  
229 for COVID-19 at 6-12 months after infection<sup>6</sup>. Consistent with these findings, a recent study  
230 of 113 COVID-19 patients with proteomic profiling and longitudinal follow-up showed that  
231 participants who developed long COVID exhibited persistent complement activation (e.g.,  
232 higher levels of C5bC6 and lower levels of C7-containing complexes) and altered coagulation  
233 (e.g., higher levels of von Willebrand factor and FXI) at 6 months after acute infection in

234 comparison with those who did not develop long COVID<sup>7</sup>. Some proteins such as von  
235 Willebrand factor and complement C5 did not receive genetic support from the present study,  
236 potentially because these proteins may represent markers of disease rather than being  
237 causal mediators or because they act downstream of other proteins or external factors with  
238 stronger causal effects. In contrast, circulating FXI, which was significantly higher in patients  
239 with vs. without long COVID<sup>7</sup>, had a strong and robust genetic association with long COVID  
240 in the present study. Collectively, these findings suggest that thromboinflammation is  
241 involved in SARS-CoV-2-associated disease beyond acute infection and support the notion  
242 that FXI contributes to the development of long COVID. Future work should test  
243 pharmacological inhibition of FXI in animal models of long COVID and potentially human  
244 trials to establish clinical efficacy and evaluate when during the disease course patients  
245 would benefit the most from FXI inhibition.

246         Although this study benefitted from multiple large-scale and well-profiled datasets, as  
247 well as a robust framework for causal inference using human genetics, certain limitations  
248 must be considered when interpreting the study findings. First, we only examined 49 proteins  
249 involved in the complement and coagulation cascades. This targeted approach was chosen  
250 based on observational data showing differences in the levels of circulating complement- and  
251 coagulation-related proteins in individuals with vs. without long COVID<sup>7</sup> and considering the  
252 importance of triangulating evidence from different research approaches for causal inference  
253 using MR<sup>15,43</sup>. Nevertheless, there may be other proteins and mediators with causal roles in  
254 long COVID. Second, we only tested genetic instruments constructed using data from  
255 European-ancestry cohorts, limiting generalizability to other ancestries. Although more than  
256 99% of participants from the Long COVID Host Genetics Initiative's GWAS had European  
257 ancestry, participants with other ancestries were also included, potentially leading to bias due  
258 to population stratification. Third, the cross-sectional nature of data collection for our  
259 analyses precluded longitudinal analyses evaluating the associations of genetically predicted  
260 FXI with long COVID in a longitudinal manner. It remains unclear if FXI mediates long COVID  
261 by aggravating the acute disease manifestations of COVID-19 or if it represents a separate  
262 mechanism that manifests during the months after acute infection. Fourth, any associations  
263 of genetically predicted FXI with viral persistence or burden after acute infection could not be  
264 evaluated. Fifth, analyses tested the association of genetically predicted FXI with postviral  
265 fatigue were underpowered and require further dedicated research. Sixth, because  
266 circulating protein levels were quantified as relative normalized protein expression units,  
267 derived effect estimates may not be representative of the absolute magnitude of effect.  
268 Assuming that plasma FXI activity is normally distributed in the general population with a  
269 mean of ~100% and a SD of ~20%<sup>44</sup>, and that pharmacological inhibition of FXI leads to a  
270 reduction of FXI activity to ~0%<sup>28</sup>, extrapolation of our findings (i.e., an OR of 1.17 for long

271 COVID per SD increase in genetically predicted FXI levels) suggests that pharmacological  
272 reduction of FXI activity from 100% to 0% could be associated with an OR of 0.46 for long  
273 COVID. Nevertheless, this extrapolation remains speculative and true effect sizes remain to  
274 be established in intervention trials. Finally, while MR can be used to infer causality in certain  
275 exposure-outcome relationships, any causal inference using MR relies on justification of the  
276 different MR assumptions. Our study used a *cis*-MR framework facilitating adherence to  
277 these assumptions<sup>11,12</sup>, included different sensitivity analyses to probe the robustness of the  
278 study findings, and replicated these using data from an external cohort. Nevertheless,  
279 genetic associations must be validated in randomized controlled trials for clinical translation.

280 In summary, this study used genetic data from multiple cohorts to investigate the  
281 relationship between the complement and coagulation systems and long COVID. Primary  
282 analyses identified a strong association of circulating FXI with long COVID risk, which was  
283 corroborated using different sensitivity analyses and replicated using data from an external  
284 cohort. These findings suggest that FXI is causally involved in long COVID, which has  
285 potential implications for the development of therapeutic interventions. Further research is  
286 needed to elucidate other molecular mechanisms and explore the effectiveness and safety of  
287 targeting circulating FXI for the prevention and/or treatment of long COVID.

288

## 289 **Methods**

### 290 *Cis-MR and instrumental variable assumptions*

291 MR analyses can be used to infer causality in certain exposure-outcome  
292 relationships, given that these analyses adheres to three key instrumental variable  
293 assumptions<sup>15</sup> (**Fig. 1**). First, the tested genetic instrument must comprise genetic variants  
294 that are associated with the exposure of interest (i.e., relevance assumption). Second, no  
295 unmeasured confounders can affect the association between the genetic variants comprising  
296 the tested genetic instrument and the outcome (i.e., independence assumption). Third, there  
297 can be no horizontal pleiotropy in the association of the tested genetic instrument with the  
298 outcome, meaning that the tested genetic instrument can only affect the outcome through its  
299 effects on the exposure of interest (i.e., exclusion restriction assumption).

300 The present study used a *cis*-MR approach, which tests genetic instruments  
301 constructed using variants associated with circulating protein levels that map near the  
302 corresponding protein-encoding gene (i.e., *cis*-pQTLs). The use of *cis*-pQTLs has beneficial  
303 effects on the adherence to the instrumental variable assumptions<sup>23,24</sup>. Variants located near  
304 the protein-encoding gene often have large effects on protein expression in comparison to  
305 other traits and are less prone to violating the “no horizontal pleiotropy” assumption than  
306 variants located elsewhere in the genome<sup>23,24</sup>. In addition, MR analyses using *cis*-pQTLs  
307 reduce the risk of reverse causation because it is more likely that *cis*-pQTLs influence protein

308 levels, which then influence a disease, rather than the disease influencing protein levels  
309 through *cis*-pQTLs.

310

### 311 *GWAS of circulating complement- and coagulation-related proteins*

312 Complement- or coagulation-related proteins were defined as those included in the  
313 “*Complement and coagulation cascades*” gene set from the KEGG database<sup>22</sup>

314 (**Supplementary Table 2**). Genetic association data were obtained for plasma levels of 49  
315 complement- or coagulation-related proteins measured in the UK Biobank<sup>9,45</sup>

316 (**Supplementary Table 3**). GWASs for circulating protein levels included up to 34,557 UK  
317 Biobank participants of European ancestry<sup>9</sup>. Blood samples donated by these participants

318 were analyzed for proteomic profiling using the Olink Explore 3072 platform (Olink

319 Proteomics, Inc; Waltham, MA), which uses proximity extension assay technology to quantify

320 protein levels. Additional information on the UK Biobank and circulating protein GWASs can

321 be found in the **Supplementary Methods**.

322

### 323 *GWAS of long COVID*

324 Genetic association data for long COVID were obtained from the Long COVID Host  
325 Genetics Initiative<sup>26</sup>. Data from a total of 3,018 long COVID cases and 994,582 controls from  
326 11 individual studies were included for primary analyses (**Supplementary Table 1**).

327 Consistent with the genetic ancestry of the exposure cohort, more than 99% of participants  
328 had European ancestry. Because the UK Biobank cohort used for primary analyses only  
329 included 34,557 participants, the maximal possible sample overlap between the exposure  
330 and outcome cohorts was ~3.5%.

331 Long COVID cases and controls were defined as reported previously<sup>26</sup>. In brief, study  
332 participants were classified as long COVID cases if they had a prior test-verified SARS-CoV-  
333 2 infection and met the long COVID criteria for a minimum of three months after their SARS-  
334 CoV-2 infection or the onset of COVID-19. As reported previously, and aligning with the  
335 World Health Organization guidelines<sup>2</sup>, individuals with long COVID criteria were defined as  
336 those who (1) reported presence of COVID-19 symptoms not attributable to other diagnoses;  
337 (2) reported persistent significant limitations in daily activities; or (3) had any diagnosis codes  
338 of long COVID in their electronic health records. All cohort-specific criteria to ascertain long  
339 COVID are shown in **Supplementary Table 1**.

340 Primary analyses used population controls to increase statistical power and limit  
341 selective inclusion of certain groups within the population, which can introduce collider bias in  
342 MR studies. Population controls were defined as those who were not identified as having  
343 long COVID using the above-mentioned criteria<sup>26</sup>. Replication analyses used a stricter  
344 control definition (i.e., all individuals with a history of SARS-CoV-2 infection but without long

345 COVID criteria [cases:  $n=2,975$ ; controls:  $n=37,935$ ]). Additional details on the long COVID  
346 case and control phenotypes, including diagnosis codes and study-specific criteria, can be  
347 found in the **Supplementary Methods** and have been described previously<sup>26</sup>.

348

#### 349 *Cis-MR analyses*

350 A full description of genetic instrument construction and MR methods can be found in  
351 the **Supplementary Methods**. Genetic instruments for circulating complement- and  
352 coagulation-related proteins were constructed using *cis*-pQTLs within 200 kilobases of each  
353 protein's encoding gene. Consistent with prior *cis*-MR analyses<sup>11,12,46</sup>, all genetic instruments  
354 included sub-genome-wide significant ( $P<1\times 10^{-6}$ ) and near-uncorrelated (linkage  
355 disequilibrium  $R^2<0.1$ ) *cis*-pQTLs. MR analyses were performed using the inverse-variance  
356 weighted method accounting for between-variant correlation structure or the Wald ratio,  
357 depending on the number of *cis*-pQTLs per genetic instrument<sup>47,48</sup>.

358 Associations were presented as odds ratios (ORs) per standard deviation (SD)  
359 increase in genetically predicted protein levels, with statistical significance set at Bonferroni-  
360 corrected  $P<1.0\times 10^{-3}$ . The *TwoSampleMR*<sup>49</sup> and *MendelianRandomization*<sup>50</sup> packages in R  
361 (version 4.1.0) were used for analyses.

362

#### 363 *Sensitivity analyses*

364 All proteins with a Bonferroni-significant association in primary analyses were carried  
365 forward for sensitivity analyses using different MR approaches and genetic instrument  
366 selection parameters. First, to evaluate the possibility of horizontal pleiotropy (i.e., effects of  
367 a genetic instrument on the target outcome beyond its effects on the exposure of interest)  
368 affecting the observed associations, we performed sensitivity analyses using the pleiotropy-  
369 robust MR-Egger method accounting for between-variant correlation structure<sup>47,48</sup>. MR-Egger  
370 is an MR method used to test and correct for horizontal pleiotropy within a genetic instrument  
371 at the cost of lower precision and statistical power<sup>51</sup>. Second, because *cis*-MR analyses often  
372 rely on *cis*-pQTLs with residual correlation<sup>52</sup>, additional sensitivity analyses were conducted  
373 using genetic instruments constructed with various linkage disequilibrium  $R^2$  thresholds  
374 ( $R^2<0.001/R^2<0.01/R^2<0.1/R^2<0.2$ ). Third, as the instruments used in primary analyses were  
375 built using sub-genome-wide significant *cis*-pQTLs, genetic associations were further  
376 corroborated using various  $P$ -value thresholds ( $P<1\times 10^{-4}/P<1\times 10^{-6}/P<1\times 10^{-8}$ ). Fourth, we  
377 also performed Steiger filtering, which removes *cis*-pQTLs that explain more variation in the  
378 outcome than in the exposure of interest<sup>53</sup>, to evaluate the possibility of reverse causation  
379 affecting the observed results. Fifth, we performed colocalization analyses to exclude the  
380 possibility that there were distinct causal variants between the *cis* loci of the prioritized  
381 proteins and long COVID (**Supplementary Methods**).

382 Consistent with prior work<sup>12</sup>, protein-disease associations were considered robust if  
383 (1) the genetic association was Bonferroni-significant in primary analyses, (2) MR-Egger  
384 suggested no horizontal pleiotropy ( $P \geq 0.05$  for the intercept test or  $P < 0.05$  for the intercept  
385 test with  $P < 0.05$  for the causal test), and (3) MR estimates had a consistent direction of effect  
386 across all primary and sensitivity analyses.

387

#### 388 *Replication analyses*

389 Robust protein-disease associations were carried forward for replication analyses.  
390 First, we evaluated whether the observed associations persisted when we used stricter  
391 criteria for controls in the Long COVID Host Genetics Initiative GWAS<sup>26</sup>. Unlike our primary  
392 analyses, which used population controls (i.e., all study participants without long COVID  
393 criteria;  $n=994,582$ ), these replication analyses only included proven controls (i.e., all study  
394 participants with proven SARS-CoV-2 infection but without long COVID criteria;  $n=37,935$ ).  
395 Second, we evaluated whether the observed associations remained consistent using an  
396 external proteomics dataset. These analyses used genetic association data from an Icelandic  
397 cohort including 35,559 participants who had their circulating proteome profiled using the  
398 aptamer-based SomaScan assay (version 4; SomaLogic, Inc.; Boulder, CO) at deCODE  
399 (deCODE genetics, Inc.; Reykjavík, Iceland)<sup>10</sup>. Additional details on the deCODE cohort can  
400 be found in the **Supplementary Methods**. Two-sided  $P < 0.05$  indicated statistical  
401 significance for replication analyses.

402

#### 403 *Cis-MR analyses of bleeding, venous thromboembolism, and long COVID-resembling* 404 *phenotypes*

405 We tested the genetic associations of all complement and coagulation factors  
406 surviving sensitivity analyses with bleeding, venous thromboembolism, acute COVID-19, and  
407 a range of “long COVID-resembling” phenotypes. These long COVID-resembling phenotypes  
408 included various conditions sharing similar symptoms—yet likely distinct mechanisms—to  
409 those observed in long COVID<sup>3</sup>. The phenotypes were chosen based on prior evidence  
410 suggesting overlapping symptoms with long COVID<sup>3</sup> and were tested if they had GWAS data  
411 available in FinnGen (release 10)<sup>54</sup>. Information on the tested long COVID-resembling  
412 phenotypes can be found in **Supplementary Table 10**.

413 Genetic association data for these phenotypes were obtained from FinnGen (release  
414 10)<sup>54</sup>, which includes 412,181 participants with European ancestry. Additional information on  
415 the tested phenotypes and FinnGen can be found in the **Supplementary Methods** and  
416 **Supplementary Table 10**.

417 **References**

- 418 1. Vos, T. *et al.* Estimated Global Proportions of Individuals With Persistent Fatigue,  
419 Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in  
420 2020 and 2021. *JAMA* **328**, 1604–1615 (2022).
- 421 2. Soriano, J. B., Murthy, S., Marshall, J. C., Relan, P. & Diaz, J. V. A clinical case  
422 definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis* **22**,  
423 e102–e107 (2022).
- 424 3. Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings,  
425 mechanisms and recommendations. *Nat Rev Microbiol* **21**, 133–146 (2023).
- 426 4. Seeble, J. *et al.* Persistent Symptoms in Adult Patients 1 Year After Coronavirus  
427 Disease 2019 (COVID-19): A Prospective Cohort Study. *Clin Infect Dis* **74**, 1191–1198  
428 (2022).
- 429 5. Tran, V. T., Porcher, R., Pane, I. & Ravaud, P. Course of post COVID-19 disease  
430 symptoms over time in the ComPaRe long COVID prospective e-cohort. *Nat Commun*  
431 **13**, 1–6 (2022).
- 432 6. Taquet, M. *et al.* Acute blood biomarker profiles predict cognitive deficits 6 and 12  
433 months after COVID-19 hospitalization. *Nat Med* **29**, 2498–2508 (2023).
- 434 7. Cervia-Hasler, C. *et al.* Persistent complement dysregulation with signs of  
435 thromboinflammation in active Long Covid. *Science (1979)* **383**, 1–18 (2024).
- 436 8. Ruf, W. Immune damage in Long Covid. *Science (1979)* **383**, 262–263 (2024).
- 437 9. Sun, B. B. *et al.* Plasma proteomic associations with genetics and health in the UK  
438 Biobank. *Nature* **622**, 329–338 (2023).
- 439 10. Ferkingstad, E. *et al.* Large-scale integration of the plasma proteome with genetics  
440 and disease. *Nat Genet* **53**, 1712–1721 (2021).
- 441 11. Henry, A. *et al.* Therapeutic Targets for Heart Failure Identified Using Proteomics and  
442 Mendelian Randomization. *Circulation* **145**, 1205–1217 (2022).
- 443 12. Schuermans, A. *et al.* Genetic Associations of Circulating Cardiovascular Proteins  
444 With Gestational Hypertension and Preeclampsia. *JAMA Cardiol* (2024)  
445 doi:10.1001/JAMACARDIO.2023.4994.
- 446 13. Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian Randomization Analysis  
447 With Multiple Genetic Variants Using Summarized Data. *Genet Epidemiol* **37**, 658–665  
448 (2013).
- 449 14. Ardissino, M. *et al.* Birth weight influences cardiac structure, function, and disease risk:  
450 evidence of a causal association. *Eur Heart J* (2023)  
451 doi:10.1093/EURHEARTJ/EHAD631.
- 452 15. Davies, N. M., Holmes, M. V. & Davey Smith, G. Reading Mendelian randomisation  
453 studies: a guide, glossary, and checklist for clinicians. *BMJ* **362**, 601 (2018).

- 454 16. Sanderson, E. *et al.* Mendelian randomization. *Nature Reviews Methods Primers* **2**, 1–  
455 21 (2022).
- 456 17. Gaziano, L. *et al.* Actionable druggable genome-wide Mendelian randomization  
457 identifies repurposing opportunities for COVID-19. *Nat Med* **27**, 668–676 (2021).
- 458 18. Bovijn, J., Lindgren, C. M. & Holmes, M. V. Genetic variants mimicking therapeutic  
459 inhibition of IL-6 receptor signaling and risk of COVID-19. *Lancet Rheumatol* **2**, e658–  
460 e659 (2020).
- 461 19. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *N Engl J Med*  
462 **384**, 1491–1502 (2021).
- 463 20. Group, T. W. R. E. A. for C.-19 T. (REACT) W. *et al.* Association Between  
464 Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for  
465 COVID-19: A Meta-analysis. *JAMA* **326**, 499–518 (2021).
- 466 21. Trajanoska, K. *et al.* From target discovery to clinical drug development with human  
467 genetics. *Nature* **620**, 737–745 (2023).
- 468 22. Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic*  
469 *Acids Res* **28**, 27–30 (2000).
- 470 23. Schmidt, A. F. *et al.* Genetic drug target validation using Mendelian randomisation. *Nat*  
471 *Commun* **11**, 1–12 (2020).
- 472 24. Swerdlow, D. I. *et al.* Selecting instruments for Mendelian randomization in the wake  
473 of genome-wide association studies. *Int J Epidemiol* **45**, 1600–1616 (2016).
- 474 25. Pierce, B. L. & Burgess, S. Efficient Design for Mendelian Randomization Studies:  
475 Subsample and 2-Sample Instrumental Variable Estimators. *Am J Epidemiol* **178**,  
476 1177–1184 (2013).
- 477 26. Lammi, V. *et al.* Genome-wide Association Study of Long COVID. *medRxiv*  
478 2023.06.29.23292056  
479 <https://www.medrxiv.org/content/10.1101/2023.06.29.23292056v1> (2023)  
480 doi:10.1101/2023.06.29.23292056.
- 481 27. Zuber, V. *et al.* Combining evidence from Mendelian randomization and colocalization:  
482 Review and comparison of approaches. *Am J Hum Genet* **109**, 767–782 (2022).
- 483 28. Verhamme, P. *et al.* Abrelcimab for Prevention of Venous Thromboembolism. *N Engl*  
484 *J Med* **385**, 609–617 (2021).
- 485 29. Weitz, J. I. *et al.* Milvexian for the Prevention of Venous Thromboembolism. *N Engl J*  
486 *Med* **385**, 2161–2172 (2021).
- 487 30. Moellmer, S. A., Puy, C. & McCarty, O. J. T. Biology of factor XI. *Blood* **143**, 1445–  
488 1454 (2024).
- 489 31. De Caterina, R., Prisco, D. & Eikelboom, J. W. Factor XI inhibitors: cardiovascular  
490 perspectives. *Eur Heart J* **44**, 280–292 (2023).



- 491 32. Verstraete, A., Engelen, M. M., Van Edom, C., Vanassche, T. & Verhamme, P.  
492 Reshaping Anticoagulation: Factor XI Inhibition in Thrombosis Management.  
493 *Hamostaseologie* **44**, 49–58 (2023).
- 494 33. Kohs, T. C. L. *et al.* Activation of coagulation FXI promotes endothelial inflammation  
495 and amplifies platelet activation in a nonhuman primate model of hyperlipidemia. *Res*  
496 *Pract Thromb Haemost* **8**, 102276 (2024).
- 497 34. Kossmann, S. *et al.* Platelet-localized FXI promotes a vascular  
498 coagulationinflammatory circuit in arterial hypertension. *Sci Transl Med* **9**, (2017).
- 499 35. Tucker, E. I. *et al.* Inhibition of factor XI activation attenuates inflammation and  
500 coagulopathy while improving the survival of mouse polymicrobial sepsis. *Blood* **119**,  
501 4762–4768 (2012).
- 502 36. Kohs, T. C. L. *et al.* Pharmacological targeting of coagulation factor XI attenuates  
503 experimental autoimmune encephalomyelitis in mice. *Metab Brain Dis* **38**, 2383–2391  
504 (2023).
- 505 37. Gorog, D. A. *et al.* Current and novel biomarkers of thrombotic risk in COVID-19: a  
506 Consensus Statement from the International COVID-19 Thrombosis Biomarkers  
507 Colloquium. *Nat Rev Cardiol* **19**, 475–495 (2022).
- 508 38. Conway, E. M. *et al.* Understanding COVID-19-associated coagulopathy. *Nat Rev*  
509 *Immunol* **22**, 639–649 (2022).
- 510 39. Klok, F. A. *et al.* Incidence of thrombotic complications in critically ill ICU patients with  
511 COVID-19. *Thromb Res* **191**, 145–147 (2020).
- 512 40. FitzGerald, E. S., Chen, Y., Fitzgerald, K. A. & Jamieson, A. M. Lung epithelial cell  
513 transcriptional regulation as a factor in COVID-19–associated coagulopathies. *Am J*  
514 *Respir Cell Mol Biol* **64**, 687–697 (2021).
- 515 41. Mast, A. E. *et al.* SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene  
516 expression in the lung. *Elife* **10**, (2021).
- 517 42. Martens, C. P. *et al.* Dysregulation of the kallikrein-kinin system in bronchoalveolar  
518 lavage fluid of patients with severe COVID-19. *EBioMedicine* **83**, 104195 (2022).
- 519 43. Lawlor, D. A., Tilling, K. & Smith, G. D. Triangulation in aetiological epidemiology. *Int J*  
520 *Epidemiol* **45**, 1866–1886 (2016).
- 521 44. Meijers, J. C. M., Tekelenburg, W. L. H., Bouma, B. N., Bertina, R. M. & Rosendaal, F.  
522 R. High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis. *N*  
523 *Engl J Med* **342**, 696–701 (2000).
- 524 45. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.  
525 *Nature* **562**, 203–209 (2018).
- 526 46. Schuermans, A. *et al.* Integrative proteomic analyses across common cardiac  
527 diseases yield new mechanistic insights and enhanced prediction. *medRxiv*

- 528 2023.12.19.23300218  
529 <https://www.medrxiv.org/content/10.1101/2023.12.19.23300218v1> (2023)  
530 doi:10.1101/2023.12.19.23300218.
- 531 47. Burgess, S., Zuber, V., Valdes-Marquez, E., Sun, B. B. & Hopewell, J. C. Mendelian  
532 randomization with fine-mapped genetic data: Choosing from large numbers of  
533 correlated instrumental variables. *Genet Epidemiol* **41**, 714 (2017).
- 534 48. Burgess, S., Dudbridge, F. & Thompson, S. G. Combining information on multiple  
535 instrumental variables in Mendelian randomization: comparison of allele score and  
536 summarized data methods. *Stat Med* **35**, 1880–1906 (2016).
- 537 49. Hemani, G. *et al.* The MR-base platform supports systematic causal inference across  
538 the human phenome. *Elife* **7**, (2018).
- 539 50. Yavorska, O. O. & Burgess, S. MendelianRandomization: an R package for performing  
540 Mendelian randomization analyses using summarized data. *Int J Epidemiol* **46**, 1734–  
541 1739 (2017).
- 542 51. Burgess, S. & Thompson, S. G. Interpreting findings from Mendelian randomization  
543 using the MR-Egger method. *Eur J Epidemiol* **32**, 377 (2017).
- 544 52. Gkatzionis, A., Burgess, S. & Newcombe, P. J. Statistical methods for cis-Mendelian  
545 randomization with two-sample summary-level data. *Genet Epidemiol* **47**, 3–25 (2023).
- 546 53. Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between  
547 imprecisely measured traits using GWAS summary data. *PLoS Genet* **13**, e1007081  
548 (2017).
- 549 54. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated  
550 population. *Nature* **613**, 508–518 (2023).  
551  
552

## 553 **Acknowledgements**

554 All authors want to acknowledge the participants and investigators of the FinnGen  
555 study, the UK Biobank, and the deCODE genetics cohort. T.N. is supported by a research  
556 fellowship of the Japan Society for the Promotion of Science for Young Scientists (22J30004)  
557 and by a Grant-in-Aid for Scientific Research (B) (23H02917). M.K.G. is funded by the  
558 German Research Foundation in the form of an Emmy Noether grant (GZ: GE 3461/2-1, ID  
559 512461526). B.R. is supported by a Wellcome Career Development Award fellowship  
560 (302210/Z/23/Z). H.M.O. is supported by the Academy of Finland (#1350181) and the NIH  
561 (R01AI170850). K.F. is supported by the National Institute of Health (R01HL161365), KU  
562 Leuven (C14/23/121), research foundation Flanders (FWO; G072921N). T.V. is supported by  
563 a grant from FWO (1843423N).

564

## 565 **Ethics declarations**

566 M.K.G. has consulted for Tourmaline Bio and serves in the Editorial Board of  
567 Neurology, both not relevant to this work. M.C.H. reports research funding from Genentech,  
568 consulting fees from Comanche Biopharma, and advisory board service for Miga Health, all  
569 unrelated to the present work. K.F. received research grants from Novo Nordisk and Swedish  
570 Orphan Biovitrum AB (Sobi). T.V. has participated in advisory boards and/or acted as a  
571 speaker on behalf of Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi Sankyo, Leo Pharma,  
572 Sanofi Aventis. P.V. has received research funding from Bayer, BMS, Pfizer, and Leo  
573 Pharma, and honoraria from Bayer, Pfizer, BMS, Daiichi-Sankyo, Sanofi-Aventis, Leo  
574 Pharma, Anthos Therapeutics, and Astra-Zeneca.

575

## 576 **Data availability**

577 This study used publicly available summary statistics from genome-wide association  
578 studies performed in the UK Biobank (<https://biobank.ndph.ox.ac.uk/showcase/>; <http://ukb-ppp.gwas.eu/>) the Long COVID Host Genetics Initiative  
579 (<https://my.locuszoom.org/gwas/793752/>;  
580 <https://www.medrxiv.org/content/10.1101/2023.06.29.23292056v1>), an Icelandic cohort  
581 genotyped by deCODE (<https://www.decode.com/summarydata/>), and FinnGen (release 10;  
582 <https://r10.finnngen.fi/>).

584

## 585 **Code availability**

586 Code used for the main analyses of this study will be published upon publication of the  
587 manuscript.


588

## 589 **Inclusion and ethics**

590 Inclusion and ethics standards have been reviewed where applicable.

591 **Figures**


592 **Fig. 1. Study design.**



593

594 The flow chart shows the study design and the data sources. The diagram illustrates the design and three core assumptions of Mendelian  
595 randomization (MR) analyses: (1) the tested genetic instrument must be associated with the exposure of interest; (2) there must be no  
596 confounders affecting the association between the tested genetic instrument and outcome of interest; (3) the genetic instrument can only affect  
597 the outcome through its effect on the exposure of interest (i.e., no horizontal pleiotropy). The use of genetic variants that are associated with  
598 circulating protein levels and are located near the corresponding protein-encoding gene, also known as *cis*-protein quantitative trait loci (*cis*-  
599 pQTLs), facilitates adherence to these assumptions, as discussed in the **Supplementary Methods**.


600 **Fig. 2. Primary analyses testing the associations of genetically predicted circulating complement- and coagulation-related protein**  
 601 **levels with long COVID.**



602 Genetic instruments were constructed for all complement- and coagulation-related proteins measured in up to 34,557 participants from the UK  
 603 Biobank<sup>9</sup>. The x-axis highlights all 49 proteins, for which genetic instruments were constructed using genetic variants, also known as *cis*-protein  
 604 quantitative trait loci (*cis*-pQTLs), that were strongly associated with circulating protein levels ( $P < 1 \times 10^{-6}$ ) and not in linkage disequilibrium with  
 605 each other (linkage disequilibrium  $R^2 < 0.1$ ). Data for long COVID were obtained from the Long COVID Host Genetics Initiative<sup>26</sup>. Associations of  
 606 genetic instruments for circulating proteins with long COVID were calculated using the inverse-variance weighted Mendelian randomization  
 607 (MR) method accounting for between-variant correlation. Columns with a negative value on the *y*-axis represent negative associations (i.e.,  
 608 associations for which the regression coefficient [ $\beta$ ] was negative) whereas those with a positive value represent positive associations. The  
 609 height of each bar represents the  $\log_{10}$ -transformed *P*-value of the corresponding association. Dark blue columns indicate associations reaching


610 Bonferroni significance ( $P < 1.0 \times 10^{-3}$ ); light red and blue columns indicate associations reaching nominal significance ( $P < 0.05$ ); grey columns  
611 indicate associations not reaching nominal significance ( $P \geq 0.05$ ).





612 Fig. 3. Association of genetically predicted circulating factor XI levels with long COVID in sensitivity and replication analyses.

613 Sensitivity analyses tested the association of genetically predicted factor XI levels with long COVID using the inverse-variance weighted method  
614 with genetic instruments constructed using a range of  $P$ -value (different shapes as indicated) and linkage disequilibrium  $R^2$  (different colors as  
615 indicated) thresholds to construct genetic instruments. The  $P$ -value threshold determines the minimal association strength for genetic variants  
616 included in each genetic instrument, whereas the linkage disequilibrium  $R^2$  thresholds determines the maximal allowed correlation between  
617 genetic variants in each genetic instrument. In primary analyses, associations were calculated using data from the UK Biobank (with proximity  
618 extension assay proteomics) and a broad control definition for long COVID. Replication analyses used an alternative, stricter, control definition<sup>26</sup>  
619 (“Replication using a strict control definition”) or data from an external cohort with an alternative, aptamer-based, proteomic profiling method<sup>10</sup>  
620 (“Replication in deCODE”). Long COVID phenotype definitions are as reported by Lammi *et al.*<sup>26</sup> CI indicates confidence interval; OR, odds  
621 ratio.



622 **Fig. 4. Associations of genetically predicted circulating factor XI levels with long COVID and other phenotypes.**

623 Associations of genetically predicted circulating levels of factor XI (FXI) with long COVID were calculated using the inverse-variance weighted  
624 method accounting for between-variant correlation structure. The genetic instrument for FXI was constructed using proteogenomic data from the  
625 UK Biobank<sup>9</sup> with a  $P$ -value threshold of  $1 \times 10^{-6}$  and an  $R^2$  threshold of 0.1. The association of genetically predicted circulating levels of FXI with  
626 long COVID was tested using genetic data from the Long COVID Host Genetics Initiative<sup>26</sup>. The associations of genetically predicted circulating  
627 levels of FXI with other phenotypes were tested using genetic data from FinnGen<sup>54</sup>. Higher genetically predicted circulating levels of factor XI  
628 were significantly associated with a higher risk of long COVID (depicted in blue; the blue band corresponds to the 95% confidence interval of  
629 this association). Higher genetically predicted factor XI levels were associated with a higher risk of venous thromboembolism, but not with  
630 bleeding (depicted in grey between the dotted lines). Higher genetically predicted factor XI levels were not associated with a higher risk of acute  
631 COVID-19 or conditions with clinical manifestations that overlap with long COVID (yet represent separate clinical entities). CI indicates  
632 confidence interval; OR, odds ratio.

